The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
August 29th 2025
A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.
Extended-Release Amantadine Shows Reduction in Dyskinesia Severity for Parkinson Disease
October 1st 2024Amantadine extended-release capsules, approved for levodopa-related dyskinesia and OFF episodes in Parkinson disease, offer high amantadine concentrations that peak in the time of first morning levodopa dose.
Positive 24-Month Data of Cell Therapy Bemdaneprocel in Parkinson Disease: Amit Rakhit, MD
October 1st 2024The chief medical officer and chief development officer at BlueRock Therapeutics provided perspective on newly presented data investigating a cell therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]
Mechanism Behind Ulixacaltamide to Treat Essential Tremor: Marcio Souza
October 1st 2024The president and chief executive officer at Praxis Precision Medicine provided clinical insight on the promising build of ulixacaltamide, an investigational, selective agent in development for essential tremor. [WATCH TIME: 3 minutes]
Randomized Controlled ELATE Study to Test OnabotulinumtoxinA in Upper Limb Essential Tremor
September 30th 2024ELATE, a multicenter, randomized, double-blind, placebo-controlled trial, aims to address the limitations of current oral therapies by exploring a targeted, localized treatment option.
Nocturnal and Morning Akinesia Still Prevalent After Nighttime Add-On Parkinson Medications
September 30th 2024In a post hoc analysis of the COSMOS study, 24-hour LCIG infusion led to a reduction in nocturnal and morning akinesia, though many patients continued to rely on nighttime add-on medications.
Potential of Device-Assisted Therapy for Advanced-Stage Parkinson Disease: David Devos, MD, PhD
September 29th 2024The neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]
Significance of Medtronic’s DBS System Approved for Asleep Neurosurgery
September 8th 2024Ashwini Sharan, MD, chief medical officer of Medtronic Neuromodulation, provided commentary on the FDA’s decision to approve asleep deep brain stimulation for the treatment of Parkinson disease and essential tremor.
Significance of Newly Approved IPX203 for Parkinson Disease
August 12th 2024In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.
FDA Approves Carbidopa/Levodopa ER Capsules Formulation IPX203 for Parkinson Disease
Published: August 7th 2024 | Updated: August 8th 2024Marketed as Crexont, the combination extended- and immediate-release treatment is indicated for treatment of PD, and is anticipated to be available in the United States in September 2024.
Transforming the Landscape of Parkinson Disease Care Through Patient-Centric Focus
July 26th 2024Michael Soileau, MD, FAAN, talked about a panel of specialists who discussed the evolution and multidisciplinary treatment of Parkinson disease, emphasizing patient-centered care and advanced therapeutic options.
Advances in Therapeutic Management for Parkinson Disease and Essential Tremor
July 25th 2024Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.
New FNIH Initiative Looks to Expedite Parkinson Disease Diagnosis Through Validated Biomarkers
July 23rd 2024Steve Hoffmann, MS, and Alessio Travaglia, PhD, provide commentary on a recently launched public-private partnership aimed at identifying biomarkers to better differentiate Parkinson disease from other related neurodegenerative disorders.
A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease
Published: July 22nd 2024 | Updated: July 24th 2024Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.